Intracranial Germ Cell Tumors in Adolescents and Young Adults: A 40-Year Multi-Institutional Review of Outcomes

Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):269-278. doi: 10.1016/j.ijrobp.2019.10.020. Epub 2019 Oct 22.

Abstract

Purpose: The aim of this study was to determine the practice patterns and outcomes of intracranial germ cell tumors (IGCT) in adolescents and young adults according to different therapeutic approaches.

Methods and materials: One-hundred twelve patients with IGCT aged 15 to 39 years were managed at either XX or the XY center from 1975 to 2015. The charts were retrospectively reviewed and data collected.

Results: Median duration of follow-up was 8.3 years. Ninety-four patients had germinomas, and 18 had nongerminomatous germ cell tumors (NGGCT). The primary disease sites were pineal gland (37 of 94 germinoma, 14 of 18 NGGCT) and suprasellar region (23 of 94 germinoma, 2 of 18 NGGCT). Eleven patients with germinoma (12%) and 2 patients with NGGCT (11%) had radiographic spinal metastases or positive lumbar cerebrospinal fluid cytology. Event-free survival (EFS) was 84% and overall survival (OS) was 90% at 10 years for germinoma; EFS was 71% and OS was 86% at 10 years for NGGCT. For patients with germinoma, 10-year EFS was 100% after craniospinal radiation therapy (CSRT) with chemotherapy (N = 10); 100% after whole-ventricular radiation therapy (WVRT), whole-brain radiation therapy (WBRT), or focal radiation therapy (FRT) with chemotherapy (N = 22); 90% after CSRT alone (N = 46); and 41% after WVRT, WBRT, or FRT alone (N = 16) (P < .0005). Ten-year OS was 100%, 100%, 90%, and 72%, respectively (P = .032). For patients with NGGCT, 10-year EFS was 80% after CSRT, WBRT, or WVRT plus chemotherapy (N = 10) versus 58% after FRT plus chemotherapy (N = 8) (P = .31); 10-year OS was 90% versus 58%, respectively (P = .16).

Conclusions: We report excellent overall outcomes according to treatment approach in the largest study of IGCT in adolescents and young adults to our knowledge. EFS and OS were inferior after non-CSRT without chemotherapy in germinoma.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / cerebrospinal fluid
  • Biopsy / statistics & numerical data
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / mortality
  • Brain Neoplasms / therapy*
  • Cancer Care Facilities
  • Chorionic Gonadotropin, beta Subunit, Human / blood
  • Chorionic Gonadotropin, beta Subunit, Human / cerebrospinal fluid
  • Craniospinal Irradiation
  • Disease-Free Survival
  • Female
  • Germinoma / diagnosis
  • Germinoma / mortality
  • Germinoma / secondary
  • Germinoma / therapy
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Neoplasm Recurrence, Local
  • Neoplasms, Germ Cell and Embryonal / diagnosis
  • Neoplasms, Germ Cell and Embryonal / mortality
  • Neoplasms, Germ Cell and Embryonal / secondary
  • Neoplasms, Germ Cell and Embryonal / therapy*
  • Pineal Gland
  • Pinealoma / diagnosis
  • Pinealoma / mortality
  • Pinealoma / therapy
  • Practice Patterns, Physicians'
  • Radiotherapy Dosage
  • Retrospective Studies
  • Spinal Neoplasms / diagnosis
  • Spinal Neoplasms / mortality
  • Spinal Neoplasms / secondary
  • Spinal Neoplasms / therapy
  • Testicular Neoplasms / diagnosis
  • Testicular Neoplasms / mortality
  • Testicular Neoplasms / secondary
  • Testicular Neoplasms / therapy
  • Time Factors
  • Treatment Outcome
  • Young Adult
  • alpha-Fetoproteins / analysis
  • alpha-Fetoproteins / cerebrospinal fluid

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Chorionic Gonadotropin, beta Subunit, Human
  • alpha-Fetoproteins

Supplementary concepts

  • Nonseminomatous germ cell tumor